In all, these findings highlight mtDNA damage as 1) a shared blood-based biomarker of iPD and LRRK2 PD, and 2) a potential blood-based biomarker of LRRK2 inhibition pharmacodynamics. The gene discussed is LRRK2; the disease is Parkinson disease.